Physician profile
Jonathan S Harrison
NPI 1710040399
$201.02
in general payments reported to CMS, 2019-2025
11 companies · $17.77 in 2025
The $17.77 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.57 · 2020: $41.89 · 2021: $16.57 · 2023: $25.64 · 2024: $16.58 · 2025: $17.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $35.06 | 2019 | |
| Exelixis INC. | $25.64 | 2023 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $19.52 | 2019 | |
| Abbott Laboratories | $17.77 | 2025 | Navitor |
| Janssen Biotech, INC. | $16.58 | 2024 | Rybrevant |
| Tg Therapeutics, INC. | $16.57 | 2021 | |
| Emd Serono, INC. | $15.70 | 2019 | |
| Lilly USA, LLC | $14.49 | 2020 | |
| Amgen INC. | $13.98 | 2020 | |
| Genentech USA, INC. | $13.42 | 2020 | |
| Seagen INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.